6 terminated. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 3 | 1 | Terminated 1 |
Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash - COVID-19, SARS-CoV 2 | Phase 2 | Terminated | University of California, San Francisco | 54 | 2021-03-31 | 2023-11-18 |
| Convalescent Plasma for Early Treatment of COVID-19 Convalescent Plasma (anti-SARS-CoV-2 plasma), Control (albumin 5%) - SARS-CoV 2, COVID-19 | Phase 2 | Terminated | Andrew Eisenberger | 223 | 2021-03-12 | 2024-08-28 |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) GLS-1200, Placebo - SARS-CoV 2, Infection | Phase 2 | Terminated | GeneOne Life Science, Inc. | 184 | 2020-06-10 | 2025-07-31 |
| Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine - COVID-19, SARS-CoV 2 | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2020-05-13 | 2021-11-16 |
| Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 CONVALESCENT PLASMA - COVID, SARS-CoV 2 | Phase 2 | Terminated | Azienda Ospedaliero, Universitaria Pisana | 1 | 2020-05-01 | 2020-11-12 |
COVID-19 (5) · Coronavirus Infections (2) · Acute Lung Injury (1) · Dyspnea (1) · Infections (1) · Pharyngeal Diseases (1) · Pneumonia (1) · Respiratory Distress Syndrome (1) · Virus Diseases (1)
Lung Diseases (6) · Respiratory Tract Diseases (6) · Coronaviridae Infections (5) · Nidovirales Infections (5) · Pneumonia, Viral (5) · RNA Virus Infections (5) · Respiratory Tract Infections (5) · Infections (4) · Pneumonia (4) · Virus Diseases (4) · Coronavirus Infections (3) · Lung Injury (1) · Otorhinolaryngologic Diseases (1) · Pathological Conditions, Signs and Symptoms (1) · Respiration Disorders (1)
Azithromycin (1) · Cetylpyridinium (1) · Ethanol (1) · Hydrogen Peroxide (1) · Hydroxychloroquine (1) · Water (1) · aviptadil (1) · chlorine dioxide (1)
APR Applied Pharma Research s.a. (1) · Andrew Eisenberger (1) · Azienda Ospedaliero, Universitaria Pisana (1) · GeneOne Life Science, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of California, San Francisco (1)
United States (4) · Brazil (1) · Italy (1)
Davey Smith, MD (1) · Francesco Menichetti (1) · Jessica Justman, MD (1) · Jonathan C Javitt, MD, MPH (1) · Stuart A Gansky, DrPH (1)